IN2014CN04055A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04055A
IN2014CN04055A IN4055CHN2014A IN2014CN04055A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A IN 4055CHN2014 A IN4055CHN2014 A IN 4055CHN2014A IN 2014CN04055 A IN2014CN04055 A IN 2014CN04055A
Authority
IN
India
Prior art keywords
proportion
composition
increased
disease
treat
Prior art date
Application number
Inventor
Thomas W Boileau
Jennifer Brulc
Ravindranath Sreedhar Menon
Original Assignee
Gen Mills Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Mills Inc filed Critical Gen Mills Inc
Publication of IN2014CN04055A publication Critical patent/IN2014CN04055A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A23L7/10—Cereal-derived products
    • A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
    • A23L7/126—Snacks or the like obtained by binding, shaping or compacting together cereal grains or cereal pieces, e.g. cereal bars
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Methods and compositions for treating medical conditions or improving health in which the composition is ingested in an amount sufficient to modify the proportion of bacteria in a gut microbiome of the individual ingesting the composition. The composition may comprise polydextrose or soluble corn fiber for example. The proportion of Coriobacteriaceae may be decreased to treat conditions such as elevated serum triglycerides nonalcoholic fatty liver disease metabolic syndrome obesity or type 2 diabetes. The proportion of Veillonellaceae may be increased to decrease serum cholesterol. The proportion of Faecalibacterium may be increased to treat inflammatory bowel disease or Chrohn s disease.
IN4055CHN2014 2011-11-04 2012-11-01 IN2014CN04055A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161555800P 2011-11-04 2011-11-04
PCT/US2012/063008 WO2013067146A1 (en) 2011-11-04 2012-11-01 Methods and compositions for modulating gastrointestinal bacteria to promote health

Publications (1)

Publication Number Publication Date
IN2014CN04055A true IN2014CN04055A (en) 2015-10-23

Family

ID=48192757

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4055CHN2014 IN2014CN04055A (en) 2011-11-04 2012-11-01

Country Status (11)

Country Link
US (1) US20150209383A1 (en)
EP (1) EP2773357A4 (en)
JP (1) JP2014532710A (en)
KR (1) KR20140093252A (en)
CN (1) CN104159588A (en)
AU (1) AU2012332491A1 (en)
BR (1) BR112014010660A2 (en)
CA (1) CA2854398A1 (en)
IN (1) IN2014CN04055A (en)
MX (1) MX2014005433A (en)
WO (1) WO2013067146A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312713D0 (en) * 2013-03-22 2013-08-28 Weaver Connie M Uses of soluble corn fibre for increasing colonic bacteria populations and increasing mineral absorption
GB2551642B (en) 2014-10-31 2020-09-23 Pendulum Therapeutics Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
AU2016250159A1 (en) * 2015-04-14 2017-11-09 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for endocrine system conditions
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
GB201519088D0 (en) * 2015-10-28 2015-12-09 Metabogen Ab The use of bacteria formulations
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
EP3199170B1 (en) * 2016-01-26 2021-07-28 FUJIFILM Corporation Salacia for reducing the number of intestinal bacteria, food, and pharmaceutical product thereof
SG11201807616RA (en) * 2016-03-14 2018-10-30 B Food Science Co Ltd Proliferative agent for faecalibacterium
CN109219656A (en) * 2016-09-06 2019-01-15 深圳华大生命科学研究院 Long dwell bacillus faecalis (Faecalibacterium longum) and its application
US20230149497A1 (en) 2017-06-02 2023-05-18 Goodgut S.L. Grape skin for use in the treatment of dysbiosis
JP2020532515A (en) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド Methods and compositions for the treatment of microbiome-related disorders
EP3466417A1 (en) * 2017-10-04 2019-04-10 Sorbonne Université Compounds for the prevention and treatment of glucose intolerance related conditions and obesity
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
CN109998112B (en) * 2017-12-22 2024-05-14 奥地利商艾尔柏有限公司 Use of rhodobacter sphaeroides for promoting intestinal health
US20210100831A1 (en) * 2018-02-14 2021-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Polydextrose for the treatment of inflammatory diseases
US20210239696A1 (en) * 2018-05-09 2021-08-05 Carbiotix Ab Method for measuring and improving gut health
US11376289B2 (en) 2018-05-31 2022-07-05 Bgi Shenzhen Composition and uses thereof
EP3846830A4 (en) 2018-09-05 2022-07-06 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
ES2763874B2 (en) * 2018-11-30 2020-10-13 Consejo Superior Investigacion PHASCOLARCTOBACTERIUM FAECIUM FOR USE IN THE PREVENTION AND TREATMENT OF OBESITY AND ITS COMORBIDITIES
WO2021071864A1 (en) * 2019-10-07 2021-04-15 Siolta Therapeutics, Inc. Therapeutic pharmaceutical compositions
KR102174095B1 (en) * 2019-12-11 2020-11-05 주식회사 에이치이엠 A novel strain of Enterococcus faecium HEM 200, and composition for improving gut environment comprising the strain or its culture fluid
JP2024518270A (en) * 2021-05-06 2024-05-01 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Compositions and methods for enhancing the growth of Faecalibacterium prausnitzii using at least one of inositol, erythritol, or sorbitol
WO2023092150A1 (en) 2021-11-22 2023-05-25 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0394655A (en) * 1989-09-06 1991-04-19 Otsuka Pharmaceut Co Ltd Nutrient feeding composition
JP4328473B2 (en) * 2001-04-09 2009-09-09 雪印乳業株式会社 Obesity prevention and improvement food and drink
FI20020078A (en) * 2002-01-15 2003-07-16 Danisco Stimulation of the immune system by polydextrosis
JP2003334025A (en) * 2002-05-15 2003-11-25 Toyo Shinyaku:Kk Health food
AU2003249081B2 (en) * 2002-08-06 2008-04-10 Dupont Nutrition Biosciences Aps Use of lactobacillus to produce exopolysaccharides in food and pharmaceutical compositions
GB0302872D0 (en) * 2003-02-10 2003-03-12 Univ Liverpool Treatment of inflammatory bowel disease
CN101677603A (en) * 2007-05-23 2010-03-24 泰特&莱尔组分美国公司 The edible composition that comprises the oligosaccharides composition of slowly digestible or digestion resistant
GB0903016D0 (en) * 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
US8816067B2 (en) * 2009-05-07 2014-08-26 Tate & Lyle Ingredients France SAS Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans

Also Published As

Publication number Publication date
EP2773357A4 (en) 2015-08-26
CA2854398A1 (en) 2013-05-10
KR20140093252A (en) 2014-07-25
MX2014005433A (en) 2014-08-22
JP2014532710A (en) 2014-12-08
US20150209383A1 (en) 2015-07-30
AU2012332491A1 (en) 2014-05-29
BR112014010660A2 (en) 2017-05-09
WO2013067146A1 (en) 2013-05-10
EP2773357A1 (en) 2014-09-10
CN104159588A (en) 2014-11-19

Similar Documents

Publication Publication Date Title
IN2014CN04055A (en)
Li et al. Probiotic mixture of Lactobacillus plantarum strains improves lipid metabolism and gut microbiota structure in high fat diet-fed mice
Li et al. Sinapine reduces non-alcoholic fatty liver disease in mice by modulating the composition of the gut microbiota
Xu et al. Function of Akkermansia muciniphila in obesity: interactions with lipid metabolism, immune response and gut systems
Zou et al. Rice bran attenuated obesity via alleviating dyslipidemia, browning of white adipocytes and modulating gut microbiota in high-fat diet-induced obese mice
Quezada et al. Acemannan and fructans from Aloe vera (Aloe barbadensis Miller) plants as novel prebiotics
Zeng et al. Lotus seed resistant starch regulates gut microbiota and increases short-chain fatty acids production and mineral absorption in mice
Chen et al. Bamboo-shaving polysaccharide protects against high-diet induced obesity and modulates the gut microbiota of mice
Shang et al. Characterization of fecal fat composition and gut derived fecal microbiota in high-fat diet fed rats following intervention with chito-oligosaccharide and resistant starch complexes
Song et al. Dietary anthocyanin-rich extract of açai protects from diet-induced obesity, liver steatosis, and insulin resistance with modulation of gut microbiota in mice
Zhang et al. Changes in intestinal microbiota of type 2 diabetes in mice in response to dietary supplementation with instant tea or matcha
Yuan et al. Punicic acid ameliorates obesity and liver steatosis by regulating gut microbiota composition in mice
Zhou et al. Gut microbiota might be a crucial factor in deciphering the metabolic benefits of perinatal genistein consumption in dams and adult female offspring
JP2015523362A5 (en)
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
WO2011097273A8 (en) Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl l-cysteine
MX2012012777A (en) Nuclear receptor binding agents.
NZ602249A (en) Food comprising glucomannan, xanthan gum and alginate for the treatment of metabolic disorders
WO2010136900A3 (en) Methods of using krill oil to treat risk factors for metabolic disorders and obesity
RU2014153787A (en) TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASE AND THROMBOSIS
Li et al. Crude polysaccharide extracted from Moringa oleifera leaves prevents obesity in association with modulating gut microbiota in high-fat diet-fed mice
Aoki et al. Oral administration of the Aureobasidium pullulans-derived β-glucan effectively prevents the development of high fat diet-induced fatty liver in mice
Fan et al. Research progress of gut microbiota and obesity caused by high-fat diet
Meng et al. Effect of dietary honeysuckle (Lonicera caerulea L.) supplementation on lipid metabolism, immunity and intestinal microbiota in grass carp (Ctenopharyngodon idellus)
RU2013128920A (en) METHOD FOR INHIBITING PATHOGENS USING A NUTRIENT COMPOSITION